Menu

AstraZeneca Says Obesity Pill Shows Minimal Side Effects in Early Trial

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial.

The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, showed 5.8% weight loss after four weeks of treatment among patients with type 2 diabetes, it said Monday during the ObesityWeek conference in San Antonio, Texas.

The trial of the once-daily drug—which mimics a gut hormone known as GLP-1 to control blood sugar and suppress appetite—showed no severe side effects among patients with dosages of up to 50mg.

Scroll to Top